Table 1.

Clinical data from key studies exploring mAb-based treatment in RRMM patients

Target	Drug	Combination	No patients evaluable for response	Median No of prior therapies (range)	Response rates (%)			Frequent toxicities (%, any grade AEs)	Reference
					≥PR	VGPR	CR
CD38	Daratumumab	-	42a	4 (2–12)a	36 a	5a	5a	Fatigue 40%, allergic rhinitis 24%, pyrexia 17%	Lokhorst et al. [23]
		-	106a	5 (2–14)a	29a	9a	3a	Fatigue 40%, anemia 33%, nausea 29%	Lonial et al. [24]
		Bortezomib-dexamethasone	251	2 (1–9)	83	40	19	Thrombocytopenia 58%, peripheral sensory neuropathy 47%, diarrhea 32%	Palumbo et al. [25••]
		Lenalidomide-dexamethasone	286	1 (1–11)	93	33	43	Neutropenia 59%, diarrhea 43%, fatigue 35%	Dimopoulos et al. [26••]
	Isatuximab	-	19b	6.5 (2–16)c	32	0	16	Fatigue 49%, nausea 34%, pyrexia 29%	Martin et al. [27]
		Lenalidomide-dexamethasone	22b	4.5 (1–8), 6 (1–10)d	50	23	0	Fatigue 46%, pyrexia 35%, diarrhea 31%	Vij et al. [28]
		Pomalidomide-dexamethasone	26	4(2–11)	62	31	4	Fatigue 62%, diarrhea 35%, dyspnea 31%	Mkhael et al. [29]
	MOR202	Dexamethasone	17	3(ne)	29	12	0	AE G ≥ 3: lymphopenia 39%, neutropenia 22%, anemia 17%, thrombocytopenia 17%	Raab et al. [30]
		Lenalidomide- dexamethasone or pomalidomide-dexamethasone	18	3(ne)	78	6	11	AE G ≥ 3: neutropenia 48%, lymphopenia 39%, pneumonia 17%	Raab et al. [30]
SLAMF7	Elotuzumab	-	34	4.5 (2–10)	-	-	-	Chills 32%, pyrexia 18%, flushing 12%	Zonder et al. [31]
		Bortezomib-dexamethasone	77	1 (1–3)	66	33	4	Infections 67%, diarrhea 44%, constipation 40%	Jakubowiak et al. [32]
		Lenalidomide-dexamethasone	321	2(1–4)	79	28	4	Lymphopenia 99%, anemia 96%, thrombocytopenia 84%, neutropenia 82%	Lonial et al. [33•]
PD-1	Nivolumab Pembrolizumab	-	27	nr	0	0	0	Skinc (pruritus, rash) 18%, fatiguec 17%, pneumonitisc 11%.	Lesokhin et al. [34]
		Lenalidomide-dexamethasone	50	nr	50	13	3	Thrombocytopenia 28%, neutropenia 24%	Mateos et al. [35]
		pomalidomide-dexamethasone	45	3 (2–6)	65	20	9	AE G ≥ 3: neutropenia 40%, hyperglycemia 25%, upper respiratory tract infections 21%	Badros et al. [36•]

SLAMF7 signaling lymphocytic activation molecule family member 7, PD-1 programmed cell death protein 1, PR partial response, VGPR very good partial response, CR complete response, AE adverse event, G grade, NCT clinicaltrials.gov registry number, nr not reported

^aData refers to the 16 mg/kg daratumumab dose

^bData refers to patients treated with doses ≥10 mg/kg

^cMedian number across entire study population

^dIsatuximab 10 and 20 mg/kg cohort, respectively